Plain-English translation of NCT07020247 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a combination approach for advanced rectal cancer that has spread to nearby lymph nodes or invaded deep into the rectal wall. Some patients will receive radiation therapy plus combined with serplulimab, an immune-boosting medication, while others will receive radiation and alone. The goal is to see if adding this medication helps more patients achieve a complete response to treatment—meaning the cancer either disappears completely or shrinks enough that doctors can safely avoid surgery.
Advanced rectal cancers near the anus are difficult to treat because surgery can damage the sphincter muscles that control bowel function. This trial is exploring whether the medication can make the cancer more responsive to radiation and , potentially allowing more patients to avoid surgery altogether or preserve their normal bowel function.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will receive treatment over several months. First, you'll have two rounds of plus the study medication (if assigned to that group) before radiation begins. Then, you'll receive daily radiation therapy for 5–6 weeks while continuing and the study medication. After radiation ends, you'll receive two more cycles of . About 3–4 weeks after treatment finishes, doctors will scan your tumor to see how you've responded; depending on the results, you may proceed to surgery or enter a careful monitoring period instead.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
China